Our Investors

Built on robust science.
Backed by impact investors.
Ready to scale.

SugaROx is supported by a blend of mission-driven investors and public innovation agencies, all aligned around a single belief: biostimulants will become the fourth pillar of modern crop production.

Image

Why Biostimulants?

Valued at USD $3B in 2021, the biostimulants market is growing fast – 12% CAGR (Global Market Insights Inc., 2022). That far outpaces the single-digit growth of traditional inputs and is drawing significant investor interest.

But around 90% of products on the market today are extracts from algae, plants, or organic waste. These cocktails of ingredients lack clear modes of action, limiting their performance to modest yield gains of 2–5%.

Image

Why Now?

Until recently, weak regulation allowed a myriad of products to flood the biostimulants market. As a result, fewer than 10% of biostimulants are patented (EBIC, 2025), and price erosion followed (AgroPages, 2023).

Now, that’s changing.

Recognising biostimulants as critical to food security and climate resilience, regulators are stepping in. Under FPR 2019/1009, the EU mandates certification of composition, efficacy, and safety. Other regions are following suit.

In response, distributors are actively seeking science-backed, IP-protected biostimulants they can trust – and recommend with confidence to farmers. We’re built to deliver exactly that.

Image

Why Us?

We’ve flipped the traditional development model on its head:

  • We start with the plant’s internal bottleneck, not a crude extract
  • Our biologists identify the natural molecule limiting performance
  • Our chemists engineer plant-permeable versions of those molecules
  • We optimise dose and spray timing for practical, in-field use

Our lead product – a patented version of T6P – is now in field trials across five markets. In wheat, a single spray has shown yield increases of up to 22% – far beyond the standard 2–5% delivered by conventional biostimulants.

We are working to launch our T6P wheat biostimulant in the UK in 2027 and in the EU in 2028, and we are expanding trials in soybean and maize to enter the US and Brazilian markets shortly after.